Serum calgranulin C as a non-invasive predictor of activity among inflammatory bowel disease
- PMID: 38995671
Serum calgranulin C as a non-invasive predictor of activity among inflammatory bowel disease
Abstract
Inflammatory bowel disease is a chronic immune-mediated disorder with a relapsing and remitting course. It leads to disabling gastrointestinal symptoms, low quality of life, and a significant burden for healthcare utilization and associated costs. Therefore, non-invasive biomarkers are needed for early diagnosis and follow up to avoid the complications of invasive diagnostic procedures. Calgranulin C is a calcium binding protein with proinflammatory properties. The aim of this study was to evaluate the role of serum calgranulin C as a non-invasive biomarker for diagnosis and prediction of activity in comparison to different biomarkers and endoscopic activity scores in inflammatory bowel disease. The study included 80 inflammatory bowel disease patients (50 Ulcerative colitis and 30 Chron's patients) and 20 normal controls. Complete blood picture, C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and serum calgranulin C were measured. Colonoscopies with histopathological examination were done and different activity scoring systems assessed. Among ulcerative colitis group, serum calgranulin C was statistically significantly higher in comparison to control group [723.640±529.055 ng/ml versus 80.850±24.416 ng/ml]. Depending on the American college of gastroenterology ulcerative colitis activity index, fecal calprotectin and serum calgranulin C were statistically significantly higher among moderate to severe ulcerative colitis than those with mild activity and those in remission (p < 0.001, for both). Regarding Crohn's disease group, serum calgranulin C was statistically significantly higher in comparison to control group [759.233±797.963 ng/ml versus 80.850±24.416 ng/mL]. Depending on Crohn's disease activity index, both serum calgranulin C and fecal calprotectin were statistically significantly higher among active disease than those in remission (p < 0.001, for both). In conclusion, serum calgranulin C could be used as a non-invasive marker to predict activity and severity and to ensure remission among inflammatory bowel disease patients.
Copyright© by the Egyptian Association of Immunologists.
Similar articles
-
Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.Kurume Med J. 2021 Dec 15;66(4):209-215. doi: 10.2739/kurumemedj.MS664009. Epub 2021 Oct 25. Kurume Med J. 2021. PMID: 34690210
-
The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: a clinical study.Eur J Pediatr. 2023 Mar;182(3):1299-1308. doi: 10.1007/s00431-022-04771-7. Epub 2023 Jan 13. Eur J Pediatr. 2023. PMID: 36637538
-
Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.Int J Mol Med. 2018 Jan;41(1):107-118. doi: 10.3892/ijmm.2017.3244. Epub 2017 Nov 7. Int J Mol Med. 2018. PMID: 29115397 Free PMC article.
-
Biomarkers of inflammatory bowel disease activity.Ter Arkh. 2018 Dec 30;90(12):107-111. doi: 10.26442/00403660.2018.12.000018. Ter Arkh. 2018. PMID: 30701842 Review.
-
Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.Inflamm Bowel Dis. 2014 Apr;20(4):742-56. doi: 10.1097/01.MIB.0000442681.85545.31. Inflamm Bowel Dis. 2014. PMID: 24562174 Review.
MeSH terms
Substances
LinkOut - more resources
Research Materials